You are here
Symbicort Gains Airflow Obstruction Indication in Patients with Chronic Obstructive Pulmonary Disease
"More than 12 million Americans with COPD struggle each day to live with the debilitating symptoms of COPD," said Dr. Howard Hutchinson, Chief Medical Officer, AstraZeneca. "With the approval of SYMBICORT in COPD, patients have a new treatment option that can deliver lung function improvement and daily symptom control, together with a rapid onset of action."
COPD is the fourth leading cause of death in the nation. Along with the 12 million Americans who suffer from this disease, some estimate that there are an equal amount of people who have COPD but remain undiagnosed. COPD is a disorder encompassing two serious lung diseases - emphysema and chronic bronchitis -- which result in chronic airway inflammation and progressive loss of lung function, making it difficult to breathe normally.
The FDA approval is based on two pivotal (Phase III) efficacy and safety trials, SHINE and SUN, which evaluated more than 3,600 patients ages 40 years and older with moderate to very severe COPD. These studies demonstrated that patients using SYMBICORT pMDI 160/4.5 mcg had significantly greater mean improvements from baseline in pre-dose forced expiratory volume in one second (FEV1) averaged over the treatment period compared with formoterol 4.5 mcg and placebo.
In addition, patients using SYMBICORT had significantly greater mean improvements from baseline in 1-hour post-dose FEV1 averaged over the treatment period compared with budesonide 160 mcg and placebo. Furthermore, the median time to onset of significant bronchodilation (greater than or equal to 15% improvement in FEV1) was five minutes.
SYMBICORT was generally well-tolerated over the 12-month study, and the incidence of pneumonia was no different for SYMBICORT compared to placebo. There was a higher incidence of potential lung infections other than pneumonia (e.g., bronchitis and viral lower respiratory tract infections) in patients receiving SYMBICORT 160/4.5 mcg than in those receiving formoterol 4.5 mcg or placebo. The most common drug-related adverse events reported were nasopharyngitis (the common cold), oral candidiasis, bronchitis, sinusitis and viral upper respiratory tract infection.
"Through these pivotal studies, SYMBICORT demonstrated rapid and sustained improvements in lung function and was generally well-tolerated long-term for patients with moderate to severe COPD," said lead investigator Dr. Donald Tashkin of the University of California, Los Angeles (UCLA). "Healthcare professionals and patients with severe COPD can now consider using SYMBICORT as a treatment option to manage their symptoms and help control the disease over time."
In patients with severe to very severe COPD, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the addition of inhaled corticosteroids (ICS) to long-acting beta2-agonists (LABA), in addition to other treatment options. Common symptoms of COPD include shortness of breath, chronic cough, wheezing and excess mucus. COPD is a progressive disease, which means people with COPD can expect lung function to worsen over time. When symptoms are severe, it can be difficult for a person to perform simple, daily tasks.(4) As the disease progresses, people with COPD may eventually require long-term oxygen therapy.